LIXELLE®, β2-microglobulin adsorption column for dialysis-related amyloidosis patients

Treatment with the LIXELLE® system is indicated for dialysis-related amyloidosis patients not responding to conventional medications.[1] The LIXELLE® column is designed to adsorb β2-microglobulin. It’s filled with cellulose porous microspheres coated by hexadecyl hydrophobic group as a ligand (Figure 1).[2][3]

Figure 1

Total proteins, albumin and immunoglobulins levels and complement factors are not affected by this adsorption mechanism. [4] Clinical studies demonstrated that therapy with LIXELLE® reduced bone cysts and improved clinical amyloidosis correlated symptoms.[5][6]

LIXELLE® is used in-series with a dialyzer. The extracorporeal circuit for using LIXELLE® is schematically demonstrated in the figure shown below.

Flow scheme – LIXELLE®

LIXELLE® is available in two sizes:
LIXELLE® S-15 LIXELLE® S-35
  • adsorbing volume: 150 ml
  • priming volume: 65 ml
  • adsorbing volume: 350 ml
  • priming volume: 177 ml

 

[1] IFU LIXELLE
[2] Tani N, Kidney and Dialysis. Supplement 1995; 54-57
[3] Nakatani et al Japanese Artificial Organ 1998; 27:571-577
[4] Furuyoshi S. et al Jpn J Apheresis 12(3):152-153
[5] Kuragano T et al, Blood Purif. 2011; 32:317-322
[6] Yamamoto Y et al, Ther Apher & Dial 2011; 15(5):466-474